1093.HK CSPC Pharmaceutical Group Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:31
Aug 26
Aug 26
Chinese biotech companies are delivering massive beats.
Chinese biotech is the standout sector halfway through earnings season, with aggregate beats clearing estimates by almost 50%. Companies like Innovent Bio and CSPC are seeing massive earnings beats and positive market reactions.
MED
00:21
Feb 02
Feb 02
Long-acting obesity deals validate Korean names.
AstraZeneca's roughly 26 trillion won collaboration with China's CSPC validates the obesity market and monthly long-acting GLP-1 opportunity, pointing to related Korean names such as Peptron, G2G Bio, and D&D Pharmatech.
MED
About 1093.HK Investor Commentary
Across the available history and selected sources, Buzzberg tracks 1093.HK (CSPC Pharmaceutical Group Limited) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: David Ingles, Lee Ju-hyeon.